Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5325238 | 0.83 | — | — | |
| SCHEMBL28050060 | 0.80 | — | — | |
| SCHEMBL29194757 | 0.80 | — | — | |
| SCHEMBL18071020 | 0.78 | — | — | |
| SCHEMBL5326548 | 0.78 | TDP1 (0.35) | ALDH1A1TDP1FFAR3 | |
| SCHEMBL28543740 | 0.76 | ALDH1A1 (0.39) | ALDH1A1TDP1FFAR3TSHRSOAT1 | |
| SCHEMBL11457278 | 0.76 | — | — | |
| SCHEMBL12632949 | 0.73 | — | — | |
| SCHEMBL28845415 | 0.72 | TDP1 (0.36) | ALDH1A1TDP1FFAR3 | |
| SCHEMBL2545646 | 0.71 | ALDH1A1 (0.41) | ALDH1A1TDP1FFAR3TSHRSOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1762567-B1 | Pyrazole derivatives for treating HIV | PFIZER LTD (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20120029192-A1 | Pyrazole Derivatives | PFIZER INC | 2012-02-02 | — | — | US | disclosed |
| US-8063044-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090215712-A1 | PYRAZOLE DERIVATIVES | PFIZER INC | 2009-08-27 | — | — | US | disclosed |
| US-20090099209-A1 | Compounds Useful in Therapy | PFIZER INC | 2009-04-16 | — | — | US | disclosed |
| US-7482375-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-7435728-B2 | Pyrazole derivatives | PFIZER INC (US) | 2008-10-14 | — | — | US | disclosed |
| EP-1874732-A1 | PYRAZOLE DERIVATIVES AS PROGESTERONE RECEPTOR ANTAGONISTS | Pfizer Limited (GB) | 2008-01-09 | — | — | EP | disclosed |
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | disclosed |
| EP-1762567-A1 | Pyrazole derivatives for treating HIV | Pfizer Limited (GB) | 2007-03-14 | — | — | EP | disclosed |
| US-20060020012-A1 | Pyrazole derivatives | PFIZER INC | 2006-01-26 | — | — | US | disclosed |
| US-20040209862-A1 | Pyrazole derivatives | PFIZER, INC. | 2004-10-21 | — | — | US | disclosed |
| US-6750230-B2 | use treating Human Immunodeficiency Virus (HIV) , or genetically related retroviral, infection or a resulting acquired immunodeficiency syndrome (AIDS); 2-[4-(3,5-dichlorobenzyl)-3,5-diethyl-1H-pyrazol-1-yl]ethanol for example; reverse transcriptase inhibitors | PFIZER, INC. | 2004-06-15 | — | — | US | disclosed |
| EP-1377556-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | Pfizer Limited (GB) | 2004-01-07 | — | — | EP | disclosed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | disclosed |
| EP-1299361-A1 | PYRAZOLE DERIVATIVES | Pfizer Limited (GB) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002004424-A9 | PYRAZOLE DERIVATIVES | PFIZER LTD (GB) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002085860-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LIMITED (GB) | 2002-10-31 | — | — | WO | disclosed |
| US-20020032184-A1 | Pyrazole derivatives | PFIZER INC. | 2002-03-14 | — | — | US | disclosed |
| WO-2002004424-A1 | PYRAZOLE DERIVATIVES | PFIZER LIMITED (GB) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215712-A1 | PYRAZOLE DERIVATIVES | RRM2B, REV1, RRM2 | ALDH1A1 1080/4885TDP1 75/4885FFAR3 2742/4885 |
| US-20060020012-A1 | Pyrazole derivatives | PDCD11, RTF1, REV1 | ALDH1A1 997/4885TDP1 91/4885FFAR3 3275/4885 |
| US-20020032184-A1 | Pyrazole derivatives | POLRMT, TPMT, CYP3A43 | ALDH1A1 228/4885TDP1 71/4885FFAR3 2687/4885 |
| US-20120029192-A1 | Pyrazole Derivatives | POLRMT, PDCD11, DPYD | ALDH1A1 886/4885TDP1 112/4885FFAR3 3641/4885 |
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | ALDH1A1 385/4885TDP1 68/4885FFAR3 3262/4885 |
| US-20040209862-A1 | Pyrazole derivatives | POLRMT, TPMT, CYP3A43 | ALDH1A1 228/4885TDP1 71/4885FFAR3 2687/4885 |
| US-20090099209-A1 | Compounds Useful in Therapy | CBR3, CBR1, GPER1 | ALDH1A1 974/4885TDP1 4163/4885FFAR3 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.